OYST News and Press, Oyster Point Pharma Inc.

Oyster Point Pharma press release ( NASDAQ: OYST ): Q3 GAAP EPS of -$1.37 misses by $0.11 . Revenue of $5.59M (-68.8% Y/Y) misses by $8.72M . For further details see: Oyster Point Pharma GAAP EPS of -$1.37 misses by $0.11, revenue of $5.59M misses by $8.7...

TYRVAYA ® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3 ’ 22 Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Approximately 6,100 Unique Eye Care Profes...

Summary Viatris’ business is holding up better than expected, despite FX headwinds. A new path to growth clears visibility for investors as the company targets to be the next ophthalmology leader. In addition, the portion of shareholder rewards through dividends and buy...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Viatris (NASDAQ: VTRS ) issued a press release today with a slew of good news. For one thing, Viatris is acquiring two different businesses . Also, these acquisitions are expected to greatly enhance the company’...

Updated to add latest share price moves Oyster Point Pharma ( NASDAQ: OYST ), a company focused on eye disorders, announced Monday that Viatris ( NASDAQ: VTRS ) agreed to acquire it for $11.00 per share in cash plus a contingent value right (CVR). After a b...

Oyster Point Pharma ( NASDAQ: OYST ), a company focused on eye disorders, announced Monday that Viatris ( NASDAQ: VTRS ) agreed to acquire it for $11.00 per share in cash plus a contingent value right (CVR). The company said that its shareholders owning about 46% o...

Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per Share PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”), ...

PRINCETON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that ...

PRINCETON, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pha...

PRINCETON, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class ph...